Certara Welcomes Arjun Bedi to Board of Directors

Bedi brings significant expertise in strategy, growth, and execution driving technology-enabled innovation across the healthcare industry

RADNOR, PA. – 2026年3月12日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, announced today the appointment of Arjun Bedi, a life sciences and digital transformation business leader with over 36 years of experience, to its Board of Directors, effective February 2026.

Bedi brings deep experience in strategic leadership, operational execution, and digital and AI-driven transformation across the health and life sciences industries. Over his 35 year career at Accenture, he held multiple senior leadership roles and served on the Global Management Committee, accelerating growth in the life sciences and biotech segments serving many of the world’s top pharmaceutical and biotech companies, and leading the firm’s Global Strategic Client Portfolio. He is also the founder of the annual Health & Life Sciences CEO Forum, now in its 15th year, which convenes CEOs from the top 20 healthcare companies to collaborate on industry strategy and execution best practices.

“Arjun is an excellent addition to Certara’s board, bringing a powerful combination of technology fluency, growth leadership, and board governance experience,” said Jon Resnick, Chief Executive Officer. “His decades of work with many of the world’s leading pharmaceutical and biotech organizations will be invaluable in supporting greater industry adoption of biosimulation to help speed innovative new medicines to patients.”

“Certara is uniquely positioned at the intersection of biosimulation, AI, and drug development. I’ve seen firsthand how AI-enhanced biosimulation technology can unlock greater certainty in drug development assets while enhancing their commercial performance and patient impact,” said Arjun Bedi. “I'm excited to join the board as Certara is poised for accelerated growth."

Visit this webpage to learn more about our leadership and board of directors.

Certara（サターラ）について

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. 製薬、教育機関、規制当局のお客様 2,600人以上、70ヵ国にてサターラの技術やサービスが活用されています。詳細は弊社ホームページをご覧ください。